Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation (PERIGLUC1)

Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.

Study Overview

• Status: Completed
• Conditions: Peritonitis Infectious; Candida Infection
• Intervention / Treatment: Other: To evaluate the initial levels and kinetics of serum β-D-glucan

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Picardie
    • Amiens, Picardie, France, 80054
      • CHU Amiens Picardie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Major Patient (age ≥ 18 years)
• Community or associated peritonitis, operated and hospitalized in resuscitation
• Affiliation to a social security scheme

Exclusion Criteria:

• Allergy known to echinocandins
• Dying Patient
• Limitation of care
• Predictable duration of follow-up ≤ 10 days
• Transfusion within 3 months
• Patient minor, patient under guardianship or curatorship

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Patients with fungal peritonitis	Other: To evaluate the initial levels and kinetics of serum β-D-glucan; To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
Other: Patients with peritonitis without yeast	Other: To evaluate the initial levels and kinetics of serum β-D-glucan; To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood determination of serum β-D-glucan kinetics in patients with peritonitis	Blood determination of serum β-D-glucan kinetics in patients with peritonitis	28 days

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens

Publications and helpful links

General Publications

• Dupont H, Malaquin S, Villeret L, Macq PY, Ammenouche N, Tinturier F, Diouf M, Rumbach M, Chouaki T. Is ss-d-glucan Relevant for the Diagnosis and Follow-Up of Intensive Care Patients with Yeast-Complicated Intra-Abdominal Infection? J Fungi (Basel). 2022 May 6;8(5):487. doi: 10.3390/jof8050487.

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2018
• Primary Completion (Actual): August 22, 2021
• Study Completion (Actual): June 1, 2023

Study Registration Dates

• First Submitted: April 14, 2017
• First Submitted That Met QC Criteria: May 2, 2017
• First Posted (Actual): May 4, 2017

Study Record Updates

• Last Update Posted (Estimated): September 19, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections and Mycoses; Mycoses; Candidiasis
• Other Study ID Numbers: PI2016_843_0036

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No